球后注射联合云克治疗Graves眼病的疗效观察及护理  被引量:3

THERAPEUTIC EVALUATION AND NURSING CARE OF RETROBULBAR INJECTION COMBINE WITH INTRAVENOUS INJECTION OF MDP FOR OPHTHALMIC GRAVES′ DISEASE

在线阅读下载全文

作  者:吴继珍[1] 范义湘[1] 梁智欣[1] 黄凯龄[1] 李科斌[1] 

机构地区:[1]广东省第二人民医院核医学科,广东广州510317

出  处:《现代医院》2013年第1期69-70,共2页Modern Hospitals

基  金:广东省医学科研基金(编号:A2009135)

摘  要:目的探讨33例球后注射联合静脉注射云克治疗Graves眼病的疗效观察及护理。方法用甲泼尼龙琥珀酸钠20 mg+维生素B120.5ug球后注射,联合静脉注射云克11 mg(鍀[99TC]亚甲基二膦酸盐注射液),每日1次,5次为1个疗程,注射1个疗程休息2周,连续注射5个疗程,3个月后随访观察记录自觉症状、眼征情况。结果 33例(59眼)患者接受治疗,显效率30.51%(18/59),有效率62.71%(37/59),无效率6.78%(4/59),总有效率93.22%;大部分患者畏光、流泪、眼胀眼痛等症状及充血水肿、眼睑浮肿等体征得到明显改善或消失。结论球后注射联合静脉注射云克治疗甲状腺相关眼病效果显著,不良反应小,安全性高。Objective To investigate therapeutic evaluation and nursing care to 33 cases (59 eyes) of Oph- thalmic Graves' disease patients which received retrobulbar injection combine with intravenous injection of MDP. Methods Retrobulbar injection with methylpre dnisolone sodium succinate ( methylpre - dnisolone sodium succinate 20 mg+ Vitamin B12 O. 5 ixg) combine with intra - venous injection of MDP( Technetium [ 99TC ] methylene diphos- phonate injection, llmg), one time per day, 5 times for a course of treatment. Rest for two weeks after each course, continuous injection for 5 courses. To follow - up the obsetv - ation to symptoms and eye situation of patients after 3 months. Results 33 patients(59 eyes) received the treatment, significant effect rate 30. 51% (18/59),effect rate 62. 71% (37/59), in effect rate 6.78(4/59) ,total effect rate 93.22% ; The symptoms of phtophobia, watery eyes, eye pain and the sign of swelling, edema with eyelid in most patients had significant improve or disappear. Conclu- sion Effect of treatment with retrobulbar injection combine with intravenous injection of MDP to Ophthalmic Graves' disease was significant, adverse reations and safty.

关 键 词:GRAVES眼病 球后注射 云克 护理 

分 类 号:R581.1[医药卫生—内分泌]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象